RxDoctor Payments Data

Nhung le

Family · Biloxi, MSNPI 1720550221

Payments from drug & device makers

$3,894in general payments, 2019–2025

Across 124 payments — averaging $31.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$615
  • Renalytix AI, Inc.$418
  • Viiv Healthcare Company$371
  • Averitas Pharma Inc.$258
  • AbbVie$226
  • plus $573 from 14 others

What the payments were for

  • Food & beverage$3,894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,894 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$16,419
Medicare patients
83
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol92$112,762
JardianceEmpagliflozin69$91,132
TrulicityDulaglutide20$44,979
MounjaroTirzepatide28$35,177
OzempicSemaglutide29$34,361
Trijardy XrEmpaglifloz/Linaglip/Metformin16$27,724
GemtesaVibegron20$23,177
KerendiaFinerenone13$22,100
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$21,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,246
VascepaIcosapent Ethyl16$13,117
Janumet XrSitagliptin Phos/Metformin Hcl15$10,438
TradjentaLinagliptin13$6,306
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,725
Diclofenac Sodium38$2,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,432$134,279125 claims
Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta$18$125,16298 claims
Lilly USA, LLCTrulicity, Mounjaro$615$80,15648 claims
Novo NordiskOzempic$199$34,36129 claims
BayerKerendia$36$22,10013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →